ABIVAX stock
Price history
−41.56% over the period1 year: from €107.80 (November 20, 2025) to €63.00 (November 20, 2026), −41.56%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €63.00 |
| October 30, 2026 | €79.05 |
| September 30, 2026 | €87.80 |
| August 31, 2026 | €97.55 |
| July 31, 2026 | €106.30 |
| June 30, 2026 | €115.50 |
| May 29, 2026 | €113.40 |
| April 30, 2026 | €96.45 |
| March 31, 2026 | €93.60 |
| February 27, 2026 | €102.60 |
| January 30, 2026 | €94.80 |
| December 31, 2025 | €120.40 |
| November 28, 2025 | €108.00 |
| November 20, 2025 | €107.80 |
At a glance
The company
Clinical-stage biotechnology company developing immune-modulating therapeutics for chronic inflammatory diseases
Latest results
Quarter to June 30, 2026 · EPS -€1.47 (estimate -€0.72)
TickerLandia's take on ABIVAX
- Strong point: Financial strength (60/100 in its group). Weak point: Market momentum (3/100).
- “Beat the market” (France): No. 9 of 106.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−54.68% from the 52-week high
Analysts · 8 analysts
Average target€131.72+109.08% vs. price
Buy 6 · Hold 2 · Sell 0 · Buy
TickerLandia Fingerprint: ABIVAX
Compared with similar companies: very weak momentum, very low earnings stability, and very high risk.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Profitabilitylow27
How much it earns on revenue and capital.
Metric Value Position in group ROA −62.9% 4 Operating marginabove 100%: likely one-off items −6,270.4% 1 ROE −252.3% 2 Gross margin 100.0% 97 Net margin 0.0% 31 Earnings stabilityvery low12
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1,815.0% 13 Loss-making yearscounts in reverse: lower means more earnings stability 5 of 5 annual reports 11 Growthlow35
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +0.48% 8 Revenue growth (year over year) −6.80% 16 Earnings growth (year over year) +93.20% 81 Financial strengthaverage60
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.00 93 Current ratio 5.97 71 Interest coverage −8.64 16 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery weak3
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −32.96% 2 Relative strength (6 months) −37.31% 6 1-year return −41.56% 3 Distance from 200-day average −35.32% 2 Riskvery high85
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 53.3% 96 Volatility (60 days) 56.7% 95 Beta (1 year) 0.92 64
1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
ABIVAX is pricier than similar companies
ABIVAX's Price/book: 13.7, +165% against the median of a group of 10 similar companies (5.18).
Compared with 11 similar companies
| Metric | ABIVAX | Position in the group | Band |
|---|---|---|---|
| Operating margin | -6,270.4% | Low | |
| ROE | -252.3% | Low | |
| Debt/equity | 0.00 | Low | |
| Price/book | 13.7 | High | |
| Net margin | 0.0% | Low |
Grey band: the middle half of the group; tick: the median; dot: ABIVAX. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€976K
Latest quarter · Q2 2026
Net income
-€117.43M
Latest quarter · Q2 2026
Quarterly net margin
-12,032.1%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €5.52B
- EPS
- -€4.31
- Volume
- 842.42K
- Daily trading
- €11.3M
- Dividend yield
- 0.00%
How ABIVAX is changing
All resultsRevenue grew 218.2% a year on average over the last 5 years
Operating margin fell from −1,136.6% to −5,384.1%
Shares outstanding up 385.1% in 5 years
Returns
ABIVAX returns
€1,000 invested in ABIVAX 5 years ago, on November 22, 2021, would be worth €2,409 today: +140.92% in total, +19.25% per year. This is the price return only: dividends are excluded.
| Period | ABIVAX | CAC 40 | €1,000 becomes |
|---|---|---|---|
| 1 month | −24.32% | +1.14% | €757 |
| 6 months | −38.78% | −2.34% | €612 |
| Year to date | −47.67% | −2.72% | €523 |
| 1 year | −41.56% | −0.67% | €584 |
| 3 years | +510.47% | +9.39% | €6,105 |
| 5 years | +140.92% | +11.58% | €2,409 |
| 10 years | +726.77% | +75.02% | €8,268 |
Over the last 6 months it has done better than 3% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
ABIVAX: technical analysis
ABIVAX is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 53.3% below its all-time closing high (€135.00, July 3, 2026).
- Trend
- Downward
- RSI (14 sessions)
- 27
- Below 30: a strong fall in a short time
- vs 200-session average
- −35.32%
Active signals
New 52-week low.
Close below the low of the previous 55 sessions.
RSI below 30: the stock has fallen a lot in a short time.
Trading on November 20, 2026 was 7.4 times the 20-session average.
Support and resistance
Price areas where ABIVAX has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€91.55+45.32%5 touches, last on April 30, 2026
- Resistance€87.80+39.37%2 touches, last on September 30, 2026
- Resistance€85.05+35.00%2 touches, last on November 12, 2026
- Last price€63.00
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved roughly in line with the CAC 40.
- Beta (1 year) vs CAC 40
- 0.92
- Volatility (60 sessions, annualised)
- 56.7%
- Largest fall in the last year
- −53.33%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
ABIVAX and its competitors
Obefazimod, the lead candidate in its pipeline, is the centre of ABIVAX's work and is being evaluated in moderately to severely active ulcerative colitis, with a separate study running in Crohn's disease. The Paris-based company, a clinical-stage biotech, develops therapies that draw on the body's own regulatory mechanisms to steady the immune response in people with chronic inflammatory diseases. Its programmes are aimed at patients suffering from chronic inflammatory conditions.
- Headquarters
- Paris, France
- Employees
- 98
- Founded
- 2013
- Chief executive
- Marc M. de Garidel
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| ABIVAXABVX | $6.06B | -6,270.4% | — | −38.78% |
| Bachem HoldingBANB | $6.84B | 21.8% | 38.7 | −2.87% |
| ALK-AbellóALK.B | $7.79B | 26.6% | 38.0 | −7.14% |
| CamurusCAMX | $4.32B | 37.4% | 58.7 | +37.97% |
| Financière de TubizeTUB | $11.25B | 0.0% | 104.1 | +9.99% |
| Bavarian NordicBAVA | $2.72B | 18.1% | 12.7 | +24.00% |
Same industry or related industries, similar size. Compare ABIVAX with its competitors · Full profile
